Three more reimbursable health apps available in Germany

05

Nov 2020

In late October 2020, three more reimbursable health apps were introduced on the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM). These applications can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers.

Now besides Kalmeda and Velibra, introduced in early October 2020, three more health apps are available at the DiGA Directory: Somnio, Vivira, and Zanadio.

The Somnio (mementor DE GmbH, Germany) is a digital application for the treatment of problems related to falling asleep and staying asleep (insomnia). In the application, evidence-based and guideline-compliant content from the field of cognitive-behavioral therapy for insomnia is applied. The app is available only in German.

The Vivira (Vivira Health Lab GmbH, Germany) is a digital health application for the treatment of back, knee and hip pain in non-specific low back pain, osteoarthritis of the spine (osteochondrosis), osteoarthritis of the knee (gonarthrosis), non-specific knee pain, osteoarthritis of the hip (coxarthrosis) and non-specific hip pain via the offered movement therapy. The app is available in English and German.

The Zanadio (aidhere GmbH, Germany) is an application that helps users to reduce their weight by changing their habits in the areas of exercise, nutrition and other behavior based on the scientific concept of multimodal, conservative obesity therapy. The app is available only in German.

The statutory health insurance will fully cover the price of the apps (€464 for Somnio, €239.97 for Vivira and €499.80 for Zanadio).

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more